{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:47:08Z","timestamp":1787021228346,"version":"build-2736575974"},"reference-count":102,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The mineralocorticoid receptor (MR), classically known for its role in electrolyte homeostasis, has emerged since the early 2000s as a key regulator of adipocyte biology. MR activation induces oxidative stress and inflammation, promotes white adipogenesis, and suppresses brown fat differentiation, potentially contributing to obesity and metabolic syndrome (MetS). In mice, MR antagonists (MRAs) have shown beneficial metabolic effects by reversing adipose tissue dysfunctions, counteracting excessive expansion of fat depots, and enhancing brown adipose tissue (BAT) thermogenesis. Clinical translation remains limited, with inconsistent outcomes in individuals with overweight or obesity, and concerns about side effects of steroidal MRAs (sMRAs), particularly hyperkalemia. Nevertheless, recent data showed that MRAs are able to activate BAT in healthy individuals and in patients with familial partial lipodystrophy type 2 (FPLD2). Nonsteroidal MR antagonists (nsMRAs), such as finerenone, exhibit anti-inflammatory and antifibrotic properties in the kidney and heart, with improved safety profiles compared to sMRAs, and are currently being explored in metabolic disorders beyond cardiorenal disease. This review summarizes novel insights into MR function in adipose tissue and critically evaluates whether MR can still be considered a valid target to treat obesity and associated metabolic disorders.<\/jats:p>","DOI":"10.1210\/endocr\/bqag004","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:40:01Z","timestamp":1767876001000},"source":"Crossref","is-referenced-by-count":3,"title":["Targeting mineralocorticoid receptors to treat metabolic diseases via the adipocyte"],"prefix":"10.1210","volume":"167","author":[{"given":"Andrea","family":"Armani","sequence":"first","affiliation":[{"name":"Department for the Promotion of Human Sciences and Quality of Life, San Raffaele Roma Open University , Rome 00166 ,","place":["Italy"]},{"name":"Laboratory of Cardiovascular Endocrinology, IRCCS San Raffaele , Rome 00166 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gorini","sequence":"additional","affiliation":[{"name":"Department for the Promotion of Human Sciences and Quality of Life, San Raffaele Roma Open University , Rome 00166 ,","place":["Italy"]},{"name":"Laboratory of Cardiovascular Endocrinology, IRCCS San Raffaele , Rome 00166 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Feraco","sequence":"additional","affiliation":[{"name":"Department for the Promotion of Human Sciences and Quality of Life, San Raffaele Roma Open University , Rome 00166 ,","place":["Italy"]},{"name":"Laboratory of Cardiovascular Endocrinology, IRCCS San Raffaele , Rome 00166 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Mammi","sequence":"additional","affiliation":[{"name":"Laboratory of Cardiovascular Endocrinology, IRCCS San Raffaele , Rome 00166 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Bellucci","sequence":"additional","affiliation":[{"name":"Department for the Promotion of Human Sciences and Quality of Life, San Raffaele Roma Open University , Rome 00166 ,","place":["Italy"]},{"name":"Laboratory of Cardiovascular Endocrinology, IRCCS San Raffaele , Rome 00166 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0722-7163","authenticated-orcid":false,"given":"Massimiliano","family":"Caprio","sequence":"additional","affiliation":[{"name":"Department for the Promotion of Human Sciences and Quality of Life, San Raffaele Roma Open University , Rome 00166 ,","place":["Italy"]},{"name":"Laboratory of Cardiovascular Endocrinology, IRCCS San Raffaele , Rome 00166 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"issue":"1","key":"2026041703262692200_bqag004-B1","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/JOE-16-0661","article-title":"30 YEARS OF THE MINERALOCORTICOID RECEPTOR: evolution of the mineralocorticoid receptor: sequence, structure and function","volume":"234","author":"Baker","year":"2017","journal-title":"J Endocrinol"},{"issue":"2","key":"2026041703262692200_bqag004-B2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s00125-023-06031-1","article-title":"Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists","volume":"67","author":"Savarese","year":"2024","journal-title":"Diabetologia"},{"issue":"3","key":"2026041703262692200_bqag004-B3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.tem.2019.11.006","article-title":"Mineralocorticoid receptors in metabolic syndrome: from physiology to disease","volume":"31","author":"Feraco","year":"2020","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"2026041703262692200_bqag004-B4","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1161\/HYPERTENSIONAHA.110.155630","article-title":"The functional c.-2G&gt;C variant of the mineralocorticoid receptor modulates blood pressure, renin, and aldosterone levels","volume":"56","author":"Van Leeuwen","year":"2010","journal-title":"Hypertension"},{"key":"2026041703262692200_bqag004-B5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fphar.2017.00313","article-title":"Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis","volume":"8","author":"Tesch","year":"2017","journal-title":"Front Pharmacol"},{"issue":"2","key":"2026041703262692200_bqag004-B6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"2026041703262692200_bqag004-B7","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1096\/fj.06-7970com","article-title":"Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis","volume":"21","author":"Caprio","year":"2007","journal-title":"FASEB J"},{"issue":"7","key":"2026041703262692200_bqag004-B8","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1210\/jc.2008-0251","article-title":"Body mass Index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients","volume":"93","author":"Rossi","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026041703262692200_bqag004-B9","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1210\/jc.2009-2521","article-title":"Aldosterone production and insulin resistance in healthy adults","volume":"95","author":"Garg","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026041703262692200_bqag004-B10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/HYPERTENSIONAHA.114.04981","article-title":"Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase","volume":"66","author":"Urbanet","year":"2015","journal-title":"Hypertension"},{"issue":"3","key":"2026041703262692200_bqag004-B11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/dom.13539","article-title":"Mineralocorticoid antagonism enhances brown adipose tissue function in humans: a randomized placebo-controlled cross-over study","volume":"21","author":"Thuzar","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"2026041703262692200_bqag004-B12","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.3390\/cells12222586","article-title":"Mineralocorticoid receptor antagonism prevents type 2 familial partial lipodystrophy brown adipocyte dysfunction","volume":"12","author":"Schena","year":"2023","journal-title":"Cells"},{"issue":"1","key":"2026041703262692200_bqag004-B13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev-physiol-021909-135917","article-title":"Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics","volume":"72","author":"Huang","year":"2010","journal-title":"Annu Rev Physiol"},{"issue":"4","key":"2026041703262692200_bqag004-B14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1172\/JCI104946","article-title":"The action of aldosterone and related corticosteroids on sodium transport across the toad bladder","volume":"43","author":"Porter","year":"1964","journal-title":"J Clin Invest"},{"issue":"4","key":"2026041703262692200_bqag004-B15","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1073\/pnas.71.4.1431","article-title":"Renal aldosterone receptors: studies with [3 H]aldosterone and the anti-mineralocorticoid [3 H]spirolactone (SC-26304)","volume":"71","author":"Marver","year":"1974","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4812","key":"2026041703262692200_bqag004-B16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.3037703","article-title":"Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor","volume":"237","author":"Arriza","year":"1987","journal-title":"Science"},{"issue":"6","key":"2026041703262692200_bqag004-B17","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1460-9568.2005.04003.x","article-title":"Postnatal ontogeny of hippocampal expression of the mineralocorticoid and glucocorticoid receptors in the common marmoset monkey","volume":"21","author":"Pryce","year":"2005","journal-title":"Eur J of Neuroscience"},{"issue":"11","key":"2026041703262692200_bqag004-B18","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1210\/mend-3-11-1877","article-title":"Molecular cloning of a mineralocorticoid (type I) receptor complementary DNA from rat hippocampus","volume":"3","author":"Patel","year":"1989","journal-title":"Molecular Endocrinology"},{"issue":"6","key":"2026041703262692200_bqag004-B19","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-3956(00)00035-2","article-title":"Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain","volume":"34","author":"Patel","year":"2000","journal-title":"J Psychiatr Res"},{"key":"2026041703262692200_bqag004-B20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/bs.vh.2018.10.009","article-title":"Evolution of the mineralocorticoid receptor","volume":"109","author":"Baker","year":"2019","journal-title":"Vitam Horm"},{"key":"2026041703262692200_bqag004-B21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.steroids.2014.05.001","article-title":"Mineralocorticoid receptor in adipocytes and macrophages: a promising target to fight metabolic syndrome","volume":"91","author":"Marzolla","year":"2014","journal-title":"Steroids"},{"issue":"37","key":"2026041703262692200_bqag004-B22","doi-asserted-by":"crossref","first-page":"18578","DOI":"10.1073\/pnas.1903172116","article-title":"Molecular evolution of the switch for progesterone and spironolactone from mineralocorticoid receptor agonist to antagonist","volume":"116","author":"Fuller","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2026041703262692200_bqag004-B23","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/ijo.2014.68","article-title":"Mineralocorticoid vs glucocorticoid receptors: solo players or team mates in the control of adipogenesis?","volume":"38","author":"Armani","year":"2014","journal-title":"Int J Obes"},{"issue":"1","key":"2026041703262692200_bqag004-B24","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/oby.2004.3","article-title":"Regulation of 11\u03b2-HSD genes in human adipose tissue: influence of central obesity and weight loss","volume":"12","author":"Engeli","year":"2004","journal-title":"Obes Res"},{"issue":"8","key":"2026041703262692200_bqag004-B25","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/oby.2007.233","article-title":"11\u03b2-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization","volume":"15","author":"Paulsen","year":"2007","journal-title":"Obesity"},{"key":"2026041703262692200_bqag004-B26","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1002\/j.2040-4603.2017.tb00777.x","article-title":"Impact of adrenal steroids on regulation of adipose tissue","volume":"7","author":"Infante","year":"2017","journal-title":"Compr Physiol"},{"issue":"25","key":"2026041703262692200_bqag004-B27","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"2026041703262692200_bqag004-B28","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","article-title":"Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria","volume":"112","author":"Quinkler","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"2026041703262692200_bqag004-B29","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"issue":"4","key":"2026041703262692200_bqag004-B30","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.110.163287","article-title":"Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function","volume":"57","author":"Lother","year":"2011","journal-title":"Hypertension"},{"issue":"4","key":"2026041703262692200_bqag004-B31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"issue":"26","key":"2026041703262692200_bqag004-B32","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1016\/j.lfs.2005.12.011","article-title":"Regulation of cardiac and renal mineralocorticoid receptor expression by captopril following myocardial infarction in rats","volume":"78","author":"De Resende","year":"2006","journal-title":"Life Sci"},{"issue":"23","key":"2026041703262692200_bqag004-B33","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","article-title":"Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias","volume":"111","author":"Ouvrard-Pascaud","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"2026041703262692200_bqag004-B34","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1074\/jbc.M113.519256","article-title":"The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation","volume":"289","author":"Lavall","year":"2014","journal-title":"J Biol Chem"},{"issue":"1","key":"2026041703262692200_bqag004-B35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1527-5299.2005.03722.x","article-title":"Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure","volume":"11","author":"Yoshida","year":"2005","journal-title":"Congestive Heart Failure"},{"issue":"11","key":"2026041703262692200_bqag004-B36","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes Mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"issue":"1","key":"2026041703262692200_bqag004-B37","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.kisu.2021.11.004","article-title":"Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease","volume":"12","author":"Nakamura","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"issue":"9","key":"2026041703262692200_bqag004-B38","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/01.ASN.0000086472.65806.73","article-title":"Aldosterone in chronic kidney and cardiac disease","volume":"14","author":"Hostetter","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2026041703262692200_bqag004-B39","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.mce.2011.06.038","article-title":"Aldosterone, mineralocorticoid receptor, and heart failure","volume":"350","author":"Messaoudi","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"2026041703262692200_bqag004-B40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000480652","article-title":"The role of the mineralocorticoid receptor in inflammation: focus on kidney and vasculature","volume":"46","author":"Belden","year":"2017","journal-title":"Am J Nephrol"},{"issue":"6","key":"2026041703262692200_bqag004-B41","doi-asserted-by":"crossref","first-page":"F1059","DOI":"10.1152\/ajprenal.00202.2003","article-title":"Effect of aldosterone on renal transforming growth factor-\u03b2","volume":"286","author":"Juknevicius","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"2026041703262692200_bqag004-B42","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med"},{"issue":"1-3","key":"2026041703262692200_bqag004-B43","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.regpep.2009.12.002","article-title":"Role of Rho kinase and oxidative stress in cardiac fibrosis induced by aldosterone and salt in angiotensin type 1a receptor knockout mice","volume":"160","author":"Kagiyama","year":"2010","journal-title":"Regul Pept"},{"issue":"1-2","key":"2026041703262692200_bqag004-B44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.mce.2005.03.016","article-title":"Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes","volume":"239","author":"Chun","year":"2005","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"2026041703262692200_bqag004-B45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.kisu.2021.11.006","article-title":"The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis","volume":"12","author":"Luther","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"issue":"8","key":"2026041703262692200_bqag004-B46","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"issue":"14","key":"2026041703262692200_bqag004-B47","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"2026041703262692200_bqag004-B48","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"2026041703262692200_bqag004-B49","doi-asserted-by":"crossref","first-page":"487","DOI":"10.4183\/aeb.2020.487","article-title":"The expanding class of mineralocorticoid receptor modulators: new ligands for kidney, cardiac, vascular, systemic and behavioral selective actions","volume":"16","author":"Badila","year":"2020","journal-title":"Acta Endo (Buc)"},{"issue":"24","key":"2026041703262692200_bqag004-B50","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"2026041703262692200_bqag004-B51","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2026041703262692200_bqag004-B52","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the finerenone, in addition to standard of care, on the progression of kidney disease in patients with non-diabetic chronic kidney disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2025","journal-title":"Nephrology Dialysis Transplantation"},{"key":"2026041703262692200_bqag004-B53","doi-asserted-by":"crossref","first-page":"110908","DOI":"10.1016\/j.diabres.2023.110908","article-title":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial","volume":"204","author":"Heerspink","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"2026041703262692200_bqag004-B54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/bs.vh.2018.10.005","article-title":"Adipocyte mineralocorticoid receptor","volume":"109","author":"Infante","year":"2019","journal-title":"Vitam Horm"},{"issue":"1","key":"2026041703262692200_bqag004-B55","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/cvr\/cvp191","article-title":"Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice","volume":"84","author":"Hirata","year":"2009","journal-title":"Cardiovasc Res"},{"issue":"17","key":"2026041703262692200_bqag004-B56","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-\u03b3, and proinflammatory adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"issue":"1","key":"2026041703262692200_bqag004-B57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1210\/en.2010-0674","article-title":"Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: potential implications for the treatment of metabolic syndrome","volume":"152","author":"Caprio","year":"2011","journal-title":"Endocrinology"},{"issue":"5","key":"2026041703262692200_bqag004-B58","doi-asserted-by":"crossref","first-page":"e1402","DOI":"10.1210\/clinem\/dgad653","article-title":"Leptin and insulin sensitivity: endogenous signals of metabolic homeostasis","volume":"109","author":"Dagogo-Jack","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026041703262692200_bqag004-B59","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1096\/fj.13-245415","article-title":"Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice","volume":"28","author":"Armani","year":"2014","journal-title":"FASEB J"},{"issue":"1","key":"2026041703262692200_bqag004-B60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.plefa.2005.04.010","article-title":"The adipose organ","volume":"73","author":"Cinti","year":"2005","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2026041703262692200_bqag004-B61","doi-asserted-by":"crossref","first-page":"1150059","DOI":"10.3389\/fendo.2023.1150059","article-title":"Thermogenic adipose tissue in energy regulation and metabolic health","volume":"14","author":"Xue","year":"2023","journal-title":"Front Endocrinol"},{"issue":"1","key":"2026041703262692200_bqag004-B62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2018.11.002","article-title":"New advances in adaptive thermogenesis: UCP1 and beyond","volume":"29","author":"Chouchani","year":"2019","journal-title":"Cell Metab"},{"issue":"6","key":"2026041703262692200_bqag004-B63","doi-asserted-by":"crossref","first-page":"E1244","DOI":"10.1152\/ajpendo.00600.2009","article-title":"The emergence of cold-induced brown adipocytes in mouse white fat depots is determined predominantly by white to brown adipocyte transdifferentiation","volume":"298","author":"Barbatelli","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"2026041703262692200_bqag004-B64","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1210\/en.2008-1018","article-title":"Aldosterone inhibits insulin-induced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen Species-mediated pathway in 3T3-L1 adipocytes","volume":"150","author":"Wada","year":"2009","journal-title":"Endocrinology"},{"issue":"2","key":"2026041703262692200_bqag004-B65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13105-019-00708-1","article-title":"The role of autophagy in brown and beige adipose tissue plasticity","volume":"76","author":"Cair\u00f3","year":"2020","journal-title":"J Physiol Biochem"},{"issue":"8","key":"2026041703262692200_bqag004-B66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0289-0","article-title":"Altered adipocyte differentiation and unbalanced autophagy in type 2 familial partial lipodystrophy: an in vitro and in vivo study of adipose tissue browning","volume":"51","author":"Pellegrini","year":"2019","journal-title":"Exp Mol Med"},{"issue":"9","key":"2026041703262692200_bqag004-B67","doi-asserted-by":"crossref","first-page":"12450","DOI":"10.1096\/fj.202000164R","article-title":"The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway","volume":"34","author":"Marzolla","year":"2020","journal-title":"FASEB J"},{"issue":"2","key":"2026041703262692200_bqag004-B68","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1074\/jbc.M006246200","article-title":"Peroxisome proliferator-activated receptor \u03b1 activates transcription of the brown fat uncoupling protein-1 gene","volume":"276","author":"Barber\u00e1","year":"2001","journal-title":"J Biol Chem"},{"issue":"30","key":"2026041703262692200_bqag004-B69","doi-asserted-by":"crossref","first-page":"25038","DOI":"10.1074\/jbc.M112.374041","article-title":"Lipolytic products activate peroxisome proliferator-activated receptor (PPAR) \u03b1 and \u03b4 in brown adipocytes to match fatty acid oxidation with supply","volume":"287","author":"Mottillo","year":"2012","journal-title":"J Biol Chem"},{"issue":"2","key":"2026041703262692200_bqag004-B70","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/mc.20710","article-title":"Aldosterone induces oxidative stress, oxidative DNA damage and NF-\u03baB-activation in kidney tubule cells: ALDOSTERONE INDUCES DNA DAMAGE AND NF-\u03baB","volume":"50","author":"Queisser","year":"2011","journal-title":"Mol Carcinog"},{"issue":"4","key":"2026041703262692200_bqag004-B71","first-page":"e25763","article-title":"IL-6-STAT3 signaling and premature senescence","volume":"2","author":"Kojima","year":"2013","journal-title":"JAKSTAT"},{"issue":"1","key":"2026041703262692200_bqag004-B72","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1038\/s41467-019-10688-x","article-title":"Reduced subcutaneous adipogenesis in human hypertrophic obesity is linked to senescent precursor cells","volume":"10","author":"Gustafson","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"2026041703262692200_bqag004-B73","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/HYPERTENSIONAHA.118.11873","article-title":"MR (mineralocorticoid receptor) induces adipose tissue senescence and mitochondrial dysfunction leading to vascular dysfunction in obesity","volume":"73","author":"Lefranc","year":"2019","journal-title":"Hypertension"},{"issue":"9","key":"2026041703262692200_bqag004-B74","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.2337\/db11-1523","article-title":"Dendritic cells promote macrophage infiltration and comprise a substantial proportion of obesity-associated increases in CD11c+ cells in adipose tissue and liver","volume":"61","author":"Stefanovic-Racic","year":"2012","journal-title":"Diabetes"},{"key":"2026041703262692200_bqag004-B75","doi-asserted-by":"crossref","first-page":"734229","DOI":"10.3389\/fimmu.2021.734229","article-title":"Reactive oxygen Species in macrophages: sources and targets","volume":"12","author":"Canton","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"2026041703262692200_bqag004-B76","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41467-018-04686-8","article-title":"Mitochondrial reactive oxygen species regulate the induction of CD8+ T cells by plasmacytoid dendritic cells","volume":"9","author":"Oberkampf","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"2026041703262692200_bqag004-B77","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000515117","article-title":"Innate immune cells in the adipose tissue in health and metabolic disease","volume":"14","author":"Michailidou","year":"2022","journal-title":"J Innate Immun"},{"issue":"9","key":"2026041703262692200_bqag004-B78","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J Clin Invest"},{"issue":"1","key":"2026041703262692200_bqag004-B79","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4049\/jimmunol.0802886","article-title":"Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity","volume":"184","author":"Herrada","year":"2010","journal-title":"The Journal of Immunology"},{"issue":"1","key":"2026041703262692200_bqag004-B80","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41467-024-55693-x","article-title":"The NE\/AAT\/CBG axis regulates adipose tissue glucocorticoid exposure","volume":"16","author":"Boyle","year":"2025","journal-title":"Nat Commun"},{"issue":"9","key":"2026041703262692200_bqag004-B81","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.3390\/ijms24097898","article-title":"Mechanisms of oxidative stress in metabolic syndrome","volume":"24","author":"Masenga","year":"2023","journal-title":"IJMS"},{"issue":"1","key":"2026041703262692200_bqag004-B82","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.gene.2012.05.052","article-title":"Activation of adipogenesis by lipocalin-type prostaglandin D synthase-generated \u039412-PGJ2 acting through PPAR\u03b3-dependent and independent pathways","volume":"505","author":"Fujimori","year":"2012","journal-title":"Gene"},{"issue":"33","key":"2026041703262692200_bqag004-B83","doi-asserted-by":"crossref","first-page":"29946","DOI":"10.1074\/jbc.M502927200","article-title":"Accelerated glucose intolerance, nephropathy, and atherosclerosis in prostaglandin D2 synthase knock-out mice","volume":"280","author":"Ragolia","year":"2005","journal-title":"J Biol Chem"},{"issue":"2","key":"2026041703262692200_bqag004-B84","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/JOE-18-0314","article-title":"Minor role of mature adipocyte mineralocorticoid receptor in high-fat diet-induced obesity","volume":"239","author":"Feraco","year":"2018","journal-title":"J Endocrinol"},{"issue":"1","key":"2026041703262692200_bqag004-B85","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1530\/JOE-18-0026","article-title":"Impact of MR on mature adipocytes in high-fat\/high-sucrose diet-induced obesity","volume":"239","author":"Hayakawa","year":"2018","journal-title":"J Endocrinol"},{"issue":"11","key":"2026041703262692200_bqag004-B86","doi-asserted-by":"crossref","first-page":"100449","DOI":"10.1016\/j.jlr.2023.100449","article-title":"Brown adipocyte mineralocorticoid receptor deficiency impairs metabolic regulation in diet-induced obese mice","volume":"64","author":"Chen","year":"2023","journal-title":"J Lipid Res"},{"issue":"2","key":"2026041703262692200_bqag004-B87","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1210\/jc.2005-1733","article-title":"Prevalence and characteristics of the metabolic syndrome in primary aldosteronism","volume":"91","author":"Fallo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026041703262692200_bqag004-B88","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/hr.2015.129","article-title":"Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism","volume":"39","author":"Karashima","year":"2016","journal-title":"Hypertens Res"},{"issue":"8","key":"2026041703262692200_bqag004-B89","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1161\/CIRCULATIONAHA.118.033597","article-title":"Primary aldosteronism: practical approach to diagnosis and management","volume":"138","author":"Byrd","year":"2018","journal-title":"Circulation"},{"issue":"8","key":"2026041703262692200_bqag004-B90","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1210\/jc.2015-1461","article-title":"RAAS activation is associated with visceral adiposity and insulin resistance among HIV-infected patients","volume":"100","author":"Srinivasa","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026041703262692200_bqag004-B91","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1210\/jc.2018-00330","article-title":"Randomized, placebo-controlled trial to evaluate effects of eplerenone on metabolic and inflammatory indices in HIV","volume":"103","author":"Srinivasa","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026041703262692200_bqag004-B92","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/dom.12224","article-title":"Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects","volume":"16","author":"Garg","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2026041703262692200_bqag004-B93","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s13300-024-01566-x","article-title":"Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes","volume":"15","author":"Gutgesell","year":"2024","journal-title":"Diabetes Ther"},{"issue":"8","key":"2026041703262692200_bqag004-B94","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1172\/JCI67803","article-title":"Recruited brown adipose tissue as an antiobesity agent in humans","volume":"123","author":"Yoneshiro","year":"2013","journal-title":"J Clin Invest"},{"key":"2026041703262692200_bqag004-B95","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"issue":"27","key":"2026041703262692200_bqag004-B96","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"issue":"1","key":"2026041703262692200_bqag004-B97","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40618-021-01635-z","article-title":"Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists","volume":"45","author":"Marzolla","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"2026041703262692200_bqag004-B98","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3390\/cells12050725","article-title":"Clinical Spectrum of LMNA-associated type 2 familial partial lipodystrophy: a systematic review","volume":"12","author":"Fernandez-Pombo","year":"2023","journal-title":"Cells"},{"issue":"2","key":"2026041703262692200_bqag004-B99","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/72807","article-title":"LMNA, encoding lamin A\/C, is mutated in partial lipodystrophy","volume":"24","author":"Shackleton","year":"2000","journal-title":"Nat Genet"},{"issue":"S1","key":"2026041703262692200_bqag004-B100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13023-022-02308-7","article-title":"Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins)","volume":"17","author":"Mosbah","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2026041703262692200_bqag004-B101","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/14740338.2022.2130889","article-title":"Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective","volume":"21","author":"Marzolla","year":"2022","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"2026041703262692200_bqag004-B102","doi-asserted-by":"crossref","first-page":"102637","DOI":"10.1016\/j.jchf.2025.102637","article-title":"Nonsteroidal and steroidal mineralocorticoid antagonists","volume":"13","author":"Harrington","year":"2025","journal-title":"JACC Heart Fail"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqag004\/66357378\/bqag004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/4\/bqag004\/68099729\/bqag004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/167\/4\/bqag004\/68099729\/bqag004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T07:26:47Z","timestamp":1776410807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqag004\/8422418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":102,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,6]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqag004","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,1,12]]},"article-number":"bqag004"}}